Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Daré Bioscience, Inc. develops and commercializes women’s health therapies across contraception, fertility, vaginal health, and sexual health. Its updates center on XACIATO, DARE to PLAY™ Sildenafil Cream, and investigational programs such as DARE-HPV and DARE-PTB1, an intravaginal ring program for prevention of preterm birth.
Recurring news themes include financial results, company updates, product availability through prescription and 503B channels, FDA and IND-related development milestones, clinical-program disclosures, and non-dilutive funding from government sources. Coverage also reflects Daré’s public reporting on product candidates, trials, financing, and business development.
Daré Bioscience (NASDAQ: DARE) announced that founder, President and CEO Sabrina Martucci Johnson was named to the Forbes 2026 “50 Over 50: Innovation” list, highlighting leaders making significant impact later in their careers. The recognition coincides with Daré’s effort to evolve from a predominantly clinical-stage biotech into a multi-product women’s health company with commercial revenue opportunities.
According to Daré Bioscience, its portfolio now spans contraception, sexual health, menopause, vaginal health, fertility and infectious disease, and includes the FDA-approved bacterial vaginosis treatment XACIATO, partnered with Organon; pivotal Phase 3-stage Ovaprene, an investigational hormone-free monthly intravaginal contraceptive; and additional development programs such as DARE-HPV, advancing with non-dilutive government funding. Daré recently began direct-to-consumer commercialization of Flora Sync LF5 in July 2026 and is pursuing a dual-path strategy for DARE to PLAY Sildenafil Cream, including compounded product availability while exploring a potential FDA regulatory pathway.
Daré Bioscience (Nasdaq: DARE) entered into a definitive securities purchase agreement with institutional investors for a registered direct offering of 4,379,581 shares of common stock, or pre-funded warrants in lieu thereof, at $1.37 per share ($1.3699 per pre-funded warrant), priced at-the-market under Nasdaq rules. Gross proceeds are expected to be $6.0 million before fees and expenses.
In a concurrent private placement, investors will receive Series A warrants and Series B warrants to purchase up to 4,379,581 shares each, at an exercise price of $1.37 per share. Both warrant series become exercisable only after required stockholder approval; Series A warrants have a five-year term from initial exercise, and Series B warrants have a two-year term. Closing of the registered direct offering and concurrent private placement is expected on or about August 17, 2026, subject to customary conditions, with Ladenburg Thalmann & Co. acting as exclusive placement agent.
Daré Bioscience (NASDAQ: DARE) reported second quarter 2026 revenue of $0.19 million, up from negative revenue in 2025, driven by research and development services for Gates Foundation agreements. Cost of revenues was $0.32 million. Selling, general and administrative expenses were $2.59 million and R&D expenses were $0.24 million, reflecting increased contra-R&D funding.
Net loss narrowed to $3.0 million, or $0.20 per share, versus $4.0 million, or $0.45 per share, a year earlier. As of June 30, 2026, cash and cash equivalents were $12.6 million, with a working capital deficit of $0.24 million and stockholders’ deficit of $0.56 million. The company highlighted the launch of Flora Sync LF5, upcoming DARE to PLAY Sildenafil Cream revenue, positive interim Phase 3 Ovaprene results, and initiation of the Phase 2 DARE-HPV study supported by ARPA-H and NIH funding.
Daré Bioscience (NASDAQ: DARE) will host a corporate update conference call and webcast at 4:30 PM Eastern Time on Thursday, August 13, 2026, to review second-quarter 2026 financial results and provide a company update. Investors can join by phone using conference ID 3808585 or via the Investors section of the company’s website, where the live webcast and a 90-day replay will be available.
Daré Bioscience (NASDAQ: DARE) announced a strategic collaboration with MyMenopauseRx, a telehealth platform focused exclusively on menopause care, to serve women exploring DARE to PLAY™ Sildenafil Cream. MyMenopauseRx will be featured as a menopause-specific telehealth option, providing access to specialists for lifestyle counseling, bioidentical hormonal treatment and other services via insurance or cash pay.
This option complements DARE to PLAY’s existing telehealth questionnaire and the ability to use a woman’s own provider, broadening pathways to care. According to Daré Bioscience, the collaboration supports its strategy to build a connected women’s health ecosystem that links innovative products with education, clinical expertise and access to care. MyMenopauseRx currently serves women in 42 U.S. states, with most services covered by commercial insurance, which may help reduce barriers to specialized menopause care.
Daré Bioscience (NASDAQ: DARE) launched its “Across the U.S.” Virtual Bus Tour Webinar Series, a multi-event investor engagement program hosted by President and CEO Sabrina Martucci Johnson. The live webcasts will provide corporate updates, commercial strategy insights, portfolio discussions, growth opportunities and interactive Q&A sessions.
The series will also cover Daré’s ongoing Regulation A offering and participation details. Scheduled “stops” include West Coast (July 23, 9:00 AM PT), Southern (August 5, 8:00 AM MT), Midwest (August 11, 11:30 AM CT) and East Coast (August 26, 3:30 PM ET). Replays will be available on the company’s investor website for 90 days.
Daré Bioscience (NASDAQ:DARE) announced that CEO Sabrina Martucci Johnson will participate in a Virtual Investor Closing Bell event on July 14, 2026, at 4:00 PM ET.
The live webcast and 90-day replay will be available on the company’s investor relations website.
Daré Bioscience (NASDAQ: DARE) launched Flora Sync LF5™, a non-hormonal vaginal probiotic capsule now sold direct-to-consumer via the DARE Health Hub, creating its first consumer product revenue stream. The product uses a vagina-specific Limosilactobacillus fermentum LF5 strain and costs $49 per 6-capsule box.
In a single-blind randomized trial of 100 women, 96% achieved vaginal microbiome balance within 3 days and 90% maintained balance at 2 weeks. Daré also highlighted upcoming DARE to PLAY™ Sildenafil Cream dispensing, a $10 million ARPA-H–funded Phase 2 study of DARE-HPV with topline data expected in 2027, and positive interim Phase 3 Ovaprene® results with DSMB support to continue.
Daré Bioscience (NASDAQ:DARE) discussed the upcoming June 2026 commercial launch of Flora Sync LF5™, a vagina-specific probiotic capsule designed to help restore microbiome balance and support vaginal comfort. The Virtual Investor “What This Means” segment highlighted its role as Daré’s first consumer health product and a potential source of direct product revenue within its broader women’s health strategy.
Daré Bioscience (NASDAQ:DARE) announced that President and CEO Sabrina Martucci Johnson will speak at multiple events and deliver a corporate presentation during the BIO International Convention 2026 in San Diego from June 22-25.
Sessions will cover women's health innovation, leadership, mentorship, and clinical development pathways.